Limits...
Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells.

Crane AM, Kramer P, Bui JH, Chung WJ, Li XS, Gonzalez-Garay ML, Hawkins F, Liao W, Mora D, Choi S, Wang J, Sun HC, Paschon DE, Guschin DY, Gregory PD, Kotton DN, Holmes MC, Sorscher EJ, Davis BR - Stem Cell Reports (2015)

Bottom Line: Starting with skin fibroblasts from patients diagnosed with cystic fibrosis, we derived and characterized induced pluripotent stem cell (iPSC) lines.We observed an exquisitely sensitive, homology-dependent preference for targeting one CFTR allele versus the other.The corrected cystic fibrosis iPSCs, when induced to differentiate in vitro, expressed the corrected CFTR gene; importantly, CFTR correction resulted in restored expression of the mature CFTR glycoprotein and restoration of CFTR chloride channel function in iPSC-derived epithelial cells.

View Article: PubMed Central - PubMed

Affiliation: Center for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.

Show MeSH

Related in: MedlinePlus

ZFN-Mediated Correction of ΔI507 or ΔF508 CFTR Mutations in CF iPSCs(A) Outline of methodology involving co-delivery of CFTR-specific ZFNs together with CFTR donor, followed by Cre-recombinase-mediated excision.(B) The schematic shows the expected genomic organization of a targeted CFTR allele including the WT exon 10 (shown in black) together with the pgk-puroTK selection cassette. A unique 6.4-kb hybridizing band is expected for a correctly modified clone and is apparent in the four corrected clones (17-14, 17-1, 17-16, and 17-9), but absent in the Cre-excised clones and the non-targeted clone 17 CF iPSCs.(C) Sequence chromatograms of the modified WT and unmodified ΔF508 CFTR alleles from corrected CF iPSC clones.See also Figure S1.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4400651&req=5

fig1: ZFN-Mediated Correction of ΔI507 or ΔF508 CFTR Mutations in CF iPSCs(A) Outline of methodology involving co-delivery of CFTR-specific ZFNs together with CFTR donor, followed by Cre-recombinase-mediated excision.(B) The schematic shows the expected genomic organization of a targeted CFTR allele including the WT exon 10 (shown in black) together with the pgk-puroTK selection cassette. A unique 6.4-kb hybridizing band is expected for a correctly modified clone and is apparent in the four corrected clones (17-14, 17-1, 17-16, and 17-9), but absent in the Cre-excised clones and the non-targeted clone 17 CF iPSCs.(C) Sequence chromatograms of the modified WT and unmodified ΔF508 CFTR alleles from corrected CF iPSC clones.See also Figure S1.

Mentions: The overall strategy for correction of CFTR exon 10 (CFTR legacy exon notation) mutations consisted of delivering CFTR-specific ZFNs together with a selectable CFTR donor DNA (Figure 1A). We designed ZFNs targeting CFTR exon 10, recognizing DNA sequences approximately 110 bp upstream of either the ΔI507 or ΔF508 deletions, to facilitate the correction of either mutant allele by HDR. The CFTR ZFNs were co-delivered with a plasmid encoding the CFTR donor to CF iPSCs. Puromycin-resistant colonies were initially screened via PCR and then sequenced to confirm that CFTR exon 10 was corrected via HDR. Southern blot analysis confirmed that four clones (17-1, 17-9, 17-14, and 17-16) exhibited the expected genomic organization in the corrected CFTR allele without any additional integration of pgk-puroTK sequences (Figure 1B). Sequencing of CFTR genomic DNA exon 10 sequences at targeted (wild-type [WT]) and unmodified (ΔF508) alleles for each of the four corrected clones demonstrated correction of one CFTR allele (ΔI507) per clone (Figure 1C). Transient delivery of a Cre-recombinase expression plasmid resulted in numerous puroTK-excised clones from each of the four successfully edited clones; successful excision was confirmed via PCR analysis with subsequent Cla I digestion (Figures 2A and 2B) and Southern blot analysis (Figure 1B).


Targeted correction and restored function of the CFTR gene in cystic fibrosis induced pluripotent stem cells.

Crane AM, Kramer P, Bui JH, Chung WJ, Li XS, Gonzalez-Garay ML, Hawkins F, Liao W, Mora D, Choi S, Wang J, Sun HC, Paschon DE, Guschin DY, Gregory PD, Kotton DN, Holmes MC, Sorscher EJ, Davis BR - Stem Cell Reports (2015)

ZFN-Mediated Correction of ΔI507 or ΔF508 CFTR Mutations in CF iPSCs(A) Outline of methodology involving co-delivery of CFTR-specific ZFNs together with CFTR donor, followed by Cre-recombinase-mediated excision.(B) The schematic shows the expected genomic organization of a targeted CFTR allele including the WT exon 10 (shown in black) together with the pgk-puroTK selection cassette. A unique 6.4-kb hybridizing band is expected for a correctly modified clone and is apparent in the four corrected clones (17-14, 17-1, 17-16, and 17-9), but absent in the Cre-excised clones and the non-targeted clone 17 CF iPSCs.(C) Sequence chromatograms of the modified WT and unmodified ΔF508 CFTR alleles from corrected CF iPSC clones.See also Figure S1.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4400651&req=5

fig1: ZFN-Mediated Correction of ΔI507 or ΔF508 CFTR Mutations in CF iPSCs(A) Outline of methodology involving co-delivery of CFTR-specific ZFNs together with CFTR donor, followed by Cre-recombinase-mediated excision.(B) The schematic shows the expected genomic organization of a targeted CFTR allele including the WT exon 10 (shown in black) together with the pgk-puroTK selection cassette. A unique 6.4-kb hybridizing band is expected for a correctly modified clone and is apparent in the four corrected clones (17-14, 17-1, 17-16, and 17-9), but absent in the Cre-excised clones and the non-targeted clone 17 CF iPSCs.(C) Sequence chromatograms of the modified WT and unmodified ΔF508 CFTR alleles from corrected CF iPSC clones.See also Figure S1.
Mentions: The overall strategy for correction of CFTR exon 10 (CFTR legacy exon notation) mutations consisted of delivering CFTR-specific ZFNs together with a selectable CFTR donor DNA (Figure 1A). We designed ZFNs targeting CFTR exon 10, recognizing DNA sequences approximately 110 bp upstream of either the ΔI507 or ΔF508 deletions, to facilitate the correction of either mutant allele by HDR. The CFTR ZFNs were co-delivered with a plasmid encoding the CFTR donor to CF iPSCs. Puromycin-resistant colonies were initially screened via PCR and then sequenced to confirm that CFTR exon 10 was corrected via HDR. Southern blot analysis confirmed that four clones (17-1, 17-9, 17-14, and 17-16) exhibited the expected genomic organization in the corrected CFTR allele without any additional integration of pgk-puroTK sequences (Figure 1B). Sequencing of CFTR genomic DNA exon 10 sequences at targeted (wild-type [WT]) and unmodified (ΔF508) alleles for each of the four corrected clones demonstrated correction of one CFTR allele (ΔI507) per clone (Figure 1C). Transient delivery of a Cre-recombinase expression plasmid resulted in numerous puroTK-excised clones from each of the four successfully edited clones; successful excision was confirmed via PCR analysis with subsequent Cla I digestion (Figures 2A and 2B) and Southern blot analysis (Figure 1B).

Bottom Line: Starting with skin fibroblasts from patients diagnosed with cystic fibrosis, we derived and characterized induced pluripotent stem cell (iPSC) lines.We observed an exquisitely sensitive, homology-dependent preference for targeting one CFTR allele versus the other.The corrected cystic fibrosis iPSCs, when induced to differentiate in vitro, expressed the corrected CFTR gene; importantly, CFTR correction resulted in restored expression of the mature CFTR glycoprotein and restoration of CFTR chloride channel function in iPSC-derived epithelial cells.

View Article: PubMed Central - PubMed

Affiliation: Center for Stem Cell and Regenerative Medicine, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center, Houston, TX 77030, USA.

Show MeSH
Related in: MedlinePlus